Effects of advanced glycation end-product inhibition and cross-link breakage in diabetic rats

Metabolism: Clinical and Experimental

Volumn 49, Issue 8, 2000, Pages 996-1000

  Oturai, P S ^a   Christensen, M ^a   Rolin, B ^a   Pedersen, K E ^a   Mortensen, S B ^a   Boel, E ^a  

^a BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIAMINOPHENAZINE; ALBUMIN; COLLAGEN; NNC 390028; PHENAZINE DERIVATIVE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CROSS LINKING; DRUG EFFECT; FEMALE; GLYCATION; HYPERGLYCEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; STREPTOZOCIN DIABETES; URINARY EXCRETION;

EID: 0033900066     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2000.7731     Document Type: Article

References (31)

1. Lilly Lecture 1993 - Glycation and diabetic complications
2. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence
3. Hemoglobin-AGE: A circulating marker of advanced glycosylation
4. Formation of immunochemical advanced glycosylation end-products precedes and correlates with early manifestations of renal and retinal disease in diabetes
5. Increased serum levels of advanced glycation end-products (AGES) in children and adolescents with IDDM
6. Receptor-mediated interactions of advanced glycosylation end products with cellular components within diabetic tissues
7. Advanced glycation end-products of the Maillard reaction in aortic pepsin-insoluble and pepsin-soluble collagen from diabetic rats
8. Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein
9. In-vitro glycation of glomerular-basement-membrane alters its permeability - A possible mechanism in diabetic complications
10. Effect of cross-linking on matrix permeability - A model for age-modified basement-membranes
11. The mechanism of collagen cross-linking in diabetes - A puzzle nearing resolution
12. Effects of age and diabetes mellitus on the solubility of collagen from human skin, tracheal cartilage and dura mater
13. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking
14. Chronic dosing with aminoguanidine and novel advanced glycosylation end product-formation inhibitors ameliorates cross-linking of tail tendon collagen in STZ-induced diabetic rats
15. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rats
16. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy
17. Aminoguanidine and diabetic neuropathy
18. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction
19. Prevention of diabetic vascular dysfunction by guanidines - Inhibition of nitric-oxide synthase versus advanced glycation end-product formation
20. Does nitric-oxide, an inflammatory mediator of glomerular mesangial cells, have a role in diabetic nephropathy?
21. An agent cleaving glucose-derived protein cross-links in-vitro and in-vivo
22. Depletion of nitric oxide synthase-containing neurons in the diabetic retina: Reversal by aminoguanidine
23. Anovel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes
24. Aminoguanidine reduces regional albumin clearance but not urinary albumin excretion in streptozotocin-diabetic rats
25. Effects of heparin on vascular dysfunction in diabetic rats
26. Naphthalene-2,3-dicarboxaldehyde/cyanide ion: A rationally designed fluorogenic reagent for primary amines
27. Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus
28. Effects of heparin and aminoguanidine on glomerular basement membrane thickening in diabetic rats
29. Discordant effects of guanidines on renal structure and function and on regional vascular dysfunction and collagen changes in diabetic rats
30. Relative contributions of advanced glycation and nitric-oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats
31. Rapid hydrolysis and slow alpha, beta-dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links